Tags

Type your tag names separated by a space and hit enter

Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients.
DNA Cell Biol. 2005 Aug; 24(8):521-7.DC

Abstract

To evaluate humoral immunity against the SARS-associated coronavirus (SARS-CoV), we studied the profiles of IgG antibodies to the nucleocapsid (N) and spike (S) proteins of SARS-CoV. Serum specimens from 10 SARS patients were analyzed by Western blotting and an enzyme-linked immunosorbent assay (ELISA) using purified recombinant N and truncated S (S1, S2, and S3) proteins as antigens. Western blotting results demonstrated that 100% of the SARS patients tested positive for N protein-specific antibodies, 50% for S1 protein-specific antibodies, 30% for S2 protein-specific antibodies, and 70% for S3 protein-specific antibodies. The ELISA results, which showed positive rates of IgG reactivity against recombinant proteins N, S1, S2, and S3, were, respectively, 28.57, 14.29, 14.29, and 14.29% at week 1, 77.78, 55.56, 44.44, and 66.67% at week 2, 100, 75, 75, and 87.5% at week 3, and 100, 77.78, 77.78, and 88.89% after 3 weeks. The average titers of IgG against recombinant proteins N, S1, S2, and S3 were, respectively, 691, 56, 38, and 84 after 3 weeks. These results suggest that the recombinant proteins N and S3 are potentially useful antigens for a serological diagnosis of SARS. In consideration of possible cross-reactivity among N proteins of SARS-CoV and other coronaviruses, immunoassays using recombinant N protein in combination with S3 as antigens might improve the specificity of SARS diagnoses.

Authors+Show Affiliations

National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16101351

Citation

Wang, Yanbin, et al. "Profiles of IgG Antibodies to Nucleocapsid and Spike Proteins of the SARS-associated Coronavirus in SARS Patients." DNA and Cell Biology, vol. 24, no. 8, 2005, pp. 521-7.
Wang Y, Chang Z, Ouyang J, et al. Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. DNA Cell Biol. 2005;24(8):521-7.
Wang, Y., Chang, Z., Ouyang, J., Wei, H., Yang, R., Chao, Y., Qu, J., Wang, J., & Hung, T. (2005). Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. DNA and Cell Biology, 24(8), 521-7.
Wang Y, et al. Profiles of IgG Antibodies to Nucleocapsid and Spike Proteins of the SARS-associated Coronavirus in SARS Patients. DNA Cell Biol. 2005;24(8):521-7. PubMed PMID: 16101351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. AU - Wang,Yanbin, AU - Chang,Zhaorui, AU - Ouyang,Jing, AU - Wei,Haiyan, AU - Yang,Renquan, AU - Chao,Yangong, AU - Qu,Jianguo, AU - Wang,Jianwei, AU - Hung,Tao, PY - 2005/8/17/pubmed PY - 2005/9/30/medline PY - 2005/8/17/entrez SP - 521 EP - 7 JF - DNA and cell biology JO - DNA Cell Biol VL - 24 IS - 8 N2 - To evaluate humoral immunity against the SARS-associated coronavirus (SARS-CoV), we studied the profiles of IgG antibodies to the nucleocapsid (N) and spike (S) proteins of SARS-CoV. Serum specimens from 10 SARS patients were analyzed by Western blotting and an enzyme-linked immunosorbent assay (ELISA) using purified recombinant N and truncated S (S1, S2, and S3) proteins as antigens. Western blotting results demonstrated that 100% of the SARS patients tested positive for N protein-specific antibodies, 50% for S1 protein-specific antibodies, 30% for S2 protein-specific antibodies, and 70% for S3 protein-specific antibodies. The ELISA results, which showed positive rates of IgG reactivity against recombinant proteins N, S1, S2, and S3, were, respectively, 28.57, 14.29, 14.29, and 14.29% at week 1, 77.78, 55.56, 44.44, and 66.67% at week 2, 100, 75, 75, and 87.5% at week 3, and 100, 77.78, 77.78, and 88.89% after 3 weeks. The average titers of IgG against recombinant proteins N, S1, S2, and S3 were, respectively, 691, 56, 38, and 84 after 3 weeks. These results suggest that the recombinant proteins N and S3 are potentially useful antigens for a serological diagnosis of SARS. In consideration of possible cross-reactivity among N proteins of SARS-CoV and other coronaviruses, immunoassays using recombinant N protein in combination with S3 as antigens might improve the specificity of SARS diagnoses. SN - 1044-5498 UR - https://www.unboundmedicine.com/medline/citation/16101351/Profiles_of_IgG_antibodies_to_nucleocapsid_and_spike_proteins_of_the_SARS_associated_coronavirus_in_SARS_patients_ L2 - https://www.liebertpub.com/doi/10.1089/dna.2005.24.521?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -